



427.057-1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

CHABRIER DE LASSAUNIERE et al

Serial No.: 10/681,002

Filed: October 8, 2003

For: PRODUCTION...MEDICAMENTS

Group: 1614

475 Park Avenue South New York, N.Y. 10016

June 18, 2004

### SECOND REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants are returning herewith a copy of the filing receipt for the above application and it is requested that the Patent Office issue a corrected filing receipt to show that the last two foreign applications are French applications and not Japanese applications. In addition, it is requested that the Patent Office insert reference to PCT application No. PCT/FR02/01218 filed April 9, 2002.

"Express Mail" mailing label No. 180 2004

I hereby certify that this paper or fee is being deposited with the United States Fostal Service "Express Mail Post Office to Addressee" service under 27 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.Q. Box 1450, Alexandria, VA 22313-1450

Respectfully submitted, Muserlian, Lucas and Mercanti

Charles A. Muserlian, 19,68. Attorney for Applicants Tel.# (212) 661-8000

CAM:ds Enclosures



20311

4

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE ONTED STATES DEFFARTMENT OF COMMIT United States Patent and Trademark Office Address & AMMISSIS NER FOR PATENTS PO Box 1150 Alexandra, Vinguia 22313-1450 www.nsplo.gov

FILING OR 371 ATTY.DOCKET NO DRAWINGS TOT CLMS IND CLMS ART UNIT FIL FEE REC'D APPL NO. (c) DATE 48 1662

10/681,002 10/08/2003

475 PARK AVENUE SOU]

NEW YORK, NY 10016

MUSERLIAN AND LUCAS AND MERCANTI,

1614

427.057-1

**CONFIRMATION NO. 7432** ORRECTED FILING RECEIPT

\*OC000000012388454\*

MUSERLIAN, LUCAS AND MERCANTI LLP

Date Mailed: 04/19/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

Pierre-Etienne Chabrier De Lassauniere, Paris; Jeremiah Harnett, Gif-Sur-Yvette, FRANCE; Dennis Bigg, Gif-Sur-Yvette, FRANCE; Anne-Marie Liberatore, Auffargis, FRANCE; Jacques Pommier, Paris, FRANCE; Jacques Lannoy, Blevres, FRANCE Christophe Thurieau, Paris, FRANCE,

#### Domestic Priority data as claimed by applicant

This application is a CIP of 10/089,993 04/04/2002 which is a 371 of PCT/FR00/02805 10/10/2000

#### Foreign Applications

FRANCE 99 12643 10/11/1999 FRANCE 00/10151 08/01/2000 FRANCE 00/11169 09/01/2000 JAPAN 01/04943 04/10/2001 JAPAN 02/01811 02/14/2002

If Required, Foreign Filing License Granted: 01/09/2004

Projected Publication Date: 07/08/2004

Non-Publication Request: No

Early Publication Request: No

**Title** 

Derivatives of heterocycles with 5 members, their preparation and their use as medicaments

**Preliminary Class** 

514

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).